Catalyst Calendar
Scope

Wed, Jun 10, 2026

1 updates
CGEM
7:30 AM

Cullinan Therapeutics Shares New Clinical Data Across Its Portfolio of T Cell Engager Programs Targeting CD19 and BCMA in Autoimmune Diseases

CLN-978 (CD19 TCE) EULAR data demonstrated potential for immune reset, including remissions, in both systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) CLN-978 data from the first RA multi-dose regimen cohort demonstrated robust efficacy, including clinical remission in a

Presentation / Abstract • Phase 1EULAR 2026 Congress presentation Wed, Jun 10, 2026cullinantherapeutics.com

Sat, Jun 6, 2026

1 updates
CGEM
5:15 AM

Cullinan Therapeutics Presents Initial Clinical Data for CLN-978, a CD19xCD3 T Cell Engager, at the EULAR 2026 Congress

Clinical benefit, including remissions, demonstrated in both systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) patients following a single target dose of CLN-978 Deep, dose-dependent B cell depletion observed in peripheral blood and tissue Favorable safety profile with single target

Presentation / Abstract • Phase 1Poster presentation Sat, Jun 6, 2026, 10:15 AM BSTcullinantherapeutics.com

Tue, May 26, 2026

1 updates
CGEM
7:00 AM

Cullinan Therapeutics to Host Immunology Day to Showcase Promising Initial Clinical Data in Autoimmune Diseases for CLN-978, a CD19 T Cell Engager, and Velinotamig, a BCMA T Cell Engager

New and updated clinical data to be presented from over 30 patients across systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) studies Initial data from the first multi-dose cohort of RA study to be presented Initial data from the first multi-dose cohort of velinotamig study also to

Results CallResults call Wed, Jun 10, 2026, 8:30 AM ETcullinantherapeutics.com

Tue, May 19, 2026

1 updates

Mon, May 18, 2026

1 updates
CGEM
5:00 PM

Cullinan Therapeutics to Present Initial Clinical Data for CLN-978 in Treatment-Refractory Rheumatoid Arthritis and Systemic Lupus Erythematosus at EULAR 2026 Congress

CAMBRIDGE, Mass., May 18, 2026 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM), a clinical-stage biopharmaceutical company accelerating potential first- or best-in-class, high-impact therapies in autoimmune diseases and cancer, today announced that initial clinical data from two

Presentation / Abstract • Phase 1Poster presentation Sat, Jun 6, 2026, 10:15 AM BSTcullinantherapeutics.com

Thu, May 7, 2026

1 updates

Tue, Apr 28, 2026

1 updates
CGEM
7:00 AM

U.S. Food and Drug Administration Accepts New Drug Application for Zipalertinib for the Treatment of Locally Advanced or Metastatic Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations

NDA submission based on the Phase 2b REZILIENT1 clinical trial, which demonstrated clinically meaningful and durable responses in patients with relapsed EGFR exon 20 insertion–mutated NSCLC Prescription Drug User Fee Act (PDUFA) target action date is February 27, 2027 PRINCETON, New Jersey, TOKYO,

cullinantherapeutics.com